A PROCESS OF EVALUATING FLUTAMIDE LOADED METHOXY POLY (ETHYLENE GLYCOL) POLY CAPROLACTONE (MPEG–PCL) NANOPARTICLES

Abstract

Prepare and evaluate Flutamide loaded methoxy poly (ethylene glycol) poly caprolactone (mPEG–PCL) nanoparticles for targeted delivery to the prostate cancer by the study of Fourier transform infrared studies were concluded that drug Flutamide, copolymer mPEG-PCL and stabilizer used for the formulation of nanoparticles were found to be compatible and suitable for formulations without any interactions. The various trials with influences of formulation components such as polymer, organic phase volume and surfactant on the physicochemical characteristics of nanoparticles were investigated. The results proved that formulation F7 containing 10 mg mPEG–PCL and 30 ml acetone with 1.5 % pluronic F127 produced the most ideal nanoparticles with average diameter of 79.2 nm. SEM images of formed nanoparticles showed spherical shape with smooth surface. The zeta potential of optimized formulation F7 was found to be - 41.5, which implies that it is having good stability. Flutamide loaded mPEG–PCL nanoparticle is a potential new carrier system for treatment of prostate cancer, which may overcome the problems associated with conventional formulations such as tablets.

Specification

Description:FIELD OF INVENTION:
[0001] The present invention is related to evaluate targeted delivery to the prostate cancer mainly using Flutamide loaded methoxy poly (ethylene glycol) poly caprolactone (mPEG-PCL).

BACKGROUND:
[0002] MPEG-PCL copolymers are vital synthetic biomedical materials possessing amphiphilicity, controlled biodegradability and good biocompatibility. Their application is seen in the fields of pharmaceutics medicinal chemistry, tissue engineering and nanotechnology and consequently led to other applications in the preparation of different delivery systems in the form of microspheres, micelles, poly-mersomes, implants, nanospheres, and nanogels.

[0003] mPEG-PCL encapsulates several varieties of drugs towards targeted drug and controlled drug release. Due to advanced research activities in recent times, m-PEG-PCL copolymers and their end group derived nanoparticles further the drug loading hydrophobic drugs, enhance bioavailability, escape from phagocytes, lower the burst release and increase the circulation time of drugs in systemic circulation [6]. Further, these nanoparticles gather in target places to enhance drug efficiency and diminish toxicity due to their small particle size and modified surface areas. This study aims to develop a new formulation of Flutamide loaded mPEG-PCL nanoparticles as new carriers for targeted delivery to prostate cancer.

[0004] Polycaprolactone (PCL) is observed to possess good biodegradability and biocompatibility which are essentially made use of in controlled drug delivery and tissue engineering applications in various formulations. It has compatibility with a variety of drugs which ensures uniform drug distribution in the formulation matrix and as it does not degrade for much time, drug release is facilitated up too many days. As a result of its very low Tm (61oC) and a low Tm (65oC), which retards the biodegradation and sometimes becomes an obstacle in some applications. Synthesis of PCL occurs by ring-opening polymerization of caprolactone (CL) monomers. The high olefin content gives it high degree of hydrophobicity and crystallinity resulting in the slow degradation and as such, becomes less biocompatible with soft tissues, which restricts its further clinical application/s. Therefore, PCL is usually blended or modified as copolymer.

DESCRIPTION OF FIGURES AND TABLE:
[0005] Figure (0001): illustrates chemical Structure of Mpeg-PCL

[0006] Figure (0002): illustrates IR Spectra of Flutamide

[0007] Figure (0003): illustrates IR Spectra of Flutamide + Mpeg-PCL

[0008] Figure (0004): illustrates IR Spectra of Flutamide + Mpeg-PCL + Pluronic F 127

[0009] Table (0001): illustrates 23 Factorial design of Nanoparticles

[0010] Table (0002): illustrates Frequencies of respective functional groups of Flutamide

DETAILED DESCRIPTION:
[0011] MATERIAL USED: Flutamide, Methoxy poly (ethylene glycol) poly caprolactone.

[0012] The present research is aimed to prepare and evaluate Flutamide loaded methoxy poly (ethylene glycol) poly caprolactone (mPEG-PCL) nanoparticles for targeted delivery to the prostate cancer. The nanoparticles (NPs) were prepared by 23 factorial design and nanoprecipitation method. Various trials were evaluated for surface morphology, particle size and zeta potential. The influences of three formulation excipients such as polymer, stabilizer and organic phase volume on the characterization of NPs were investigated.

[0013] The results of Fourier transform infrared (FTIR) studies were indicated no interaction between the drug and polymer. The particle size varied from 79.2 to 89.1 nm and zeta potential value was found to be - 41.5 mv. The surface morphology of NPs was observed using scanning electron microscopy (SEM) and understands the arrangement and orientation of NPs to determine its behaviour and stability. Flutamide loaded mPEG-PCL nanoparticle is a potential new carrier system for treatment of prostate cancer, which may overcome the problems associated with conventional formulations such as tablets.

[0014] Preparation of Nano particles: Flutamide loaded mPEG-PCL nanoparticles were prepared by the nanoprecipitation method [8]. Drug and polymer were dissolved in organic and this solution was added to stabilizer in PBS pH 7.4 at 1 ml/min speed using syringe under magnetic stirring conditions. The obtained suspension was stirred at 500 rpm for 2 hr to evaporate acetone. The suspension was centrifuge at 11,000 rpm for 30 minutes to remove precipitants and supernatant was collected, lyophilized and stored at 4°C.

[0015] Nanoprecipitation method was used for preparation of Flutamide loaded nanoparticles. The formulations were designed by 23 factorial design, which contained three variables like polymer concentration, stabilizer and organic solvent volume at two levels. Total eight batches were formulated (F1 - F8) and all the formulations were investigated for various parameters.

[0016] The optimization phase was carried out statistically using 23 factorial designs in which the polymer concentration, stabilizer and organic solvent volume were kept at two different levels. Total eight formulations were prepared for ease of analysis and comparison.

[0017] Drug - polymer compatibility studies: A stable and effective dosage form was formulated depends on selection of excipients that are promote the drug release and bioavailability and protect it from degradation. If the excipients not were used in formulation containing the active drug, the compatibility study is mandatory. The IR spectra of Flutamide and formulation mixture were recorded on a FT-IR spectrophotometer. About 2mg of the sample was made into pellets using KBr and hydraulic press under a pressure of 6000kg/cm2. Spectra were scanned between 4000 and 500 cm-1 at ambient temperature.

[0018] Physicochemical characterization of Nano particle the obtained formulations of Flutamide loaded mPEG-PCL nanoparticles were characterized for Particle Size Analysis, Surface Morphology and Surface Charge determination. Particle size measurement was carried out by Photon Correlation Spectroscopy (PCS) (Malvern Instruments). Samples were diluted with ultra purified water, and measured at 25° and 90° scattering angles, recorded for 180 sec and the mean diameters for all samples were obtained by cumulative analysis in triplicate. The morphological study of nanoparticles was carried out using scanning electron microscopy (SEM) (Tecnai 20 G2 S TWIN). SEM was employed to understand the arrangement and orientation of molecules within the nanoparticle to determine its behaviour and stability. Nanoparticles were characterized for Zeta potential (ζ) using a Zeta Sizer.

[0019] Fourier Transform Infra-Red Spectroscopy (FTIR): FTIR studies used to determine the interaction between Flutamide, mPEG-PCL and Pluronic F-127 used in nanoparticle preparation. The mixture of drug and excipients were prepared in 1:1 w/w ratio and used for IR analysis. The FTIR spectra of Flutamide (Fig.2) indicates that the characteristic peaks of -NO, NH, C=O and -CH2 are observed at 1344.97 cm-1, 3360.06 cm-1, 1717.71cm-1 and 3127.11cm-1respectively.

[0020] Size Analysis: NANO PARTICLES CHARACTER ANALYSIS: Formulation F7 showed minimum particle size of 79.2 nm and the formulation F6 showed maximum particle size of 89.1 nm. The results indicate that the particle size increased with increasing polymer (mPEG-PCL) concentration of 10 & 50 mg, the minimum variation in size may occurred due to capping action of the mPEG [14]. The particle size decreased with increasing organic phase volume of 10 & 30 ml and the particle size decreased with increasing Pluronic F-127 from1 - 1.5%. The particle size of NPs is important that influences accumulation in tumour tissue via EPR effect and the targeting ability of NPs after administration.

[0021] Scanning Electron Microscopy (SEM): Surface morphology of Flutamide loaded copolymeric nanoparticles was evaluated by SEM., Eight formulations of nanoparticles have regular spherical structure with smooth and uniform surface without signs of collapse.

[0022] Surface Charge (Zeta Potential): The zeta potential of the formulation F7 was found to be - 41.5, which implies that it is having good stability. The negative zeta potential values of formulation F7 can be attributed to the presence of uncapped end ionized carboxyl groups of the polymer at the particle surface.
, Claims:Claims:
I/We Claim:
1. A method of mPEG-PCL nanoparticles as new carriers for delivery of a prostate cancer drug
fluamide, comprising:
a flutamide loaded mPEG-PCL nanoparticles were prepared by the nanoprecipitation method;
drug and polymer were dissolved in organic and this solution was added to stabilizer in pbs ph 7.4
at 1 ml/min speed using syringe under magnetic stirring conditions;
the obtained suspension was stirred at 500 rpm for 2 hr to evaporate acetone;
wherein the suspension was centrifuge at 11,000 rpm for 30 minutes to remove precipitants and
supernatant was collected, lyophilized and stored at 4°c;
the optimization phase was carried out statistically using 23 factorial designs in which the polymer
concentration, stabilizer and organic solvent volume were kept at two different levels; and
total eight formulations were prepared for ease of analysis and comparison.

Documents